CMIC Group Launches New CDMO Business in Japan
CMIC Bio will offer contract development and manufacturing organization services for biopharmaceutical drug substance.
CMIC Group, a contract research organization located in Japan, announced on July 22, 2020 that it is establishing CMIC Bio, a subsidiary that will offer contract development and manufacturing organization services for biopharmaceutical drug substance.
According to a company press release, CMIC Bio’s single-use facility for process development and GMP manufacturing of antibody drugs using mammalian cell lines in Shizuoka, Japan, will be in full-scale operation starting in October 2020.
“At CMIC Bio, we have personnel with abundant experience at pharmaceutical companies and have strengths in GMP API manufacturing bases in Japan to assist in accelerating the development speed of biopharmaceuticals,” said Hiroshi Kosaku, president of CMIC Pharmaceutical Sciences, in the press release. “CMIC Group will provide end to end solutions from non-clinical testing, running clinical trial, GMP manufacturing of biopharmaceuticals to the commercialization and post market.”
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
